26 results
8-K
EX-99.2
CGTX
Cognition Therapeutics Inc
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
period and 3 in placebo period) Most common AEs by MedDRA system organ class: - GI: nausea, diarrhea - Injury & procedural complications: procedural
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
effects of our product candidates could result in patient injury or death. Any of these occurrences may materially and adversely affect our business … greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise
DRS
ljdiez0
20 Oct 22
Draft registration statement
12:00am
10-K
374t7hpv621uoyvt
30 Mar 22
Annual report
7:40am
8-K
EX-99.1
wr0clcwibe
10 Jan 22
Regulation FD Disclosure
7:01am
10-Q
bxzf2k5xozaondv
17 Nov 21
Quarterly report
5:15pm
424B4
odw3nhnqqg obex9v1
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
1o967vs2f3vvtg
19 Jul 21
IPO registration
7:02am
S-1
EX-10.4
x5r99 vdv
19 Jul 21
IPO registration
7:02am
S-1
EX-10.6
4y5kz2u0zydu
19 Jul 21
IPO registration
7:02am
S-1
EX-10.18
mysw1kcx4omxi8gkc
19 Jul 21
IPO registration
7:02am
S-1
EX-10.15
p9b8ty3
19 Jul 21
IPO registration
7:02am
S-1
EX-10.17
wa272uc 4eal57a8xn
19 Jul 21
IPO registration
7:02am